NO20022863D0 - Trans-olefiniske glycokinase aktivatorer - Google Patents

Trans-olefiniske glycokinase aktivatorer

Info

Publication number
NO20022863D0
NO20022863D0 NO20022863A NO20022863A NO20022863D0 NO 20022863 D0 NO20022863 D0 NO 20022863D0 NO 20022863 A NO20022863 A NO 20022863A NO 20022863 A NO20022863 A NO 20022863A NO 20022863 D0 NO20022863 D0 NO 20022863D0
Authority
NO
Norway
Prior art keywords
olefinic
trans
glycokinase activators
glycokinase
activators
Prior art date
Application number
NO20022863A
Other languages
English (en)
Other versions
NO323142B1 (no
NO20022863L (no
Inventor
Wendy Lea Corbett
Ramakanth Sarabu
Achyutharao Sidduri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20022863L publication Critical patent/NO20022863L/no
Publication of NO20022863D0 publication Critical patent/NO20022863D0/no
Publication of NO323142B1 publication Critical patent/NO323142B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
    • C07C275/48—Y being a hydrogen or a carbon atom
    • C07C275/50—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Detergent Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20022863A 1999-12-15 2002-06-14 Trans-olefiniske glycokinase aktivatorer, anvendelse av disse som medikament, farmasoytiske preparater inneholdende slike, anvendelse av disse for fremstilling av medikament for behandling eller forebygging av type II diabetes samt fremgangsmate for fremstilling av disse. NO323142B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17078399P 1999-12-15 1999-12-15
PCT/EP2000/012612 WO2001044216A1 (en) 1999-12-15 2000-12-12 Trans olefinic glucokinase activators

Publications (3)

Publication Number Publication Date
NO20022863L NO20022863L (no) 2002-06-14
NO20022863D0 true NO20022863D0 (no) 2002-06-14
NO323142B1 NO323142B1 (no) 2007-01-08

Family

ID=22621235

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022863A NO323142B1 (no) 1999-12-15 2002-06-14 Trans-olefiniske glycokinase aktivatorer, anvendelse av disse som medikament, farmasoytiske preparater inneholdende slike, anvendelse av disse for fremstilling av medikament for behandling eller forebygging av type II diabetes samt fremgangsmate for fremstilling av disse.

Country Status (33)

Country Link
US (1) US6353111B1 (no)
EP (1) EP1242397B1 (no)
JP (1) JP3824936B2 (no)
KR (1) KR100502032B1 (no)
CN (1) CN1185219C (no)
AR (1) AR032752A1 (no)
AT (1) ATE305461T1 (no)
AU (1) AU781029B2 (no)
CA (1) CA2392903C (no)
CO (1) CO5050295A1 (no)
CZ (1) CZ20022412A3 (no)
DE (1) DE60022903T2 (no)
DK (1) DK1242397T3 (no)
ES (1) ES2249322T3 (no)
GC (1) GC0000264A (no)
HK (1) HK1054383B (no)
HR (1) HRP20020514A2 (no)
HU (1) HUP0203753A3 (no)
IL (2) IL150083A0 (no)
JO (1) JO2180B1 (no)
MA (1) MA26855A1 (no)
MX (1) MXPA02005874A (no)
MY (1) MY125484A (no)
NO (1) NO323142B1 (no)
NZ (1) NZ518974A (no)
PE (1) PE20011022A1 (no)
PL (1) PL355815A1 (no)
RU (1) RU2245332C2 (no)
TW (1) TWI262916B (no)
UY (1) UY26483A1 (no)
WO (1) WO2001044216A1 (no)
YU (1) YU41402A (no)
ZA (1) ZA200203829B (no)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102300D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102299D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
WO2003055482A1 (en) 2001-12-21 2003-07-10 Novo Nordisk A/S Amide derivatives as gk activators
AU2003211052A1 (en) 2002-02-11 2003-09-04 Vertex Pharmaceuticals Incorporated Phospholipids as caspase inhibitor prodrugs
DE60328671D1 (de) 2002-03-26 2009-09-17 Banyu Pharma Co Ltd Neue aminobenzamidderivate
EP1531815B1 (en) 2002-06-27 2014-09-24 Novo Nordisk A/S Glucokinase activators
RU2340605C2 (ru) 2002-06-27 2008-12-10 Ново Нордиск А/С Арилкарбонильные производные в качестве терапевтических средств
NZ539013A (en) * 2002-10-03 2007-05-31 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
GB0226930D0 (en) * 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
US7132425B2 (en) 2002-12-12 2006-11-07 Hoffmann-La Roche Inc. 5-substituted-six-membered heteroaromatic glucokinase activators
WO2004063194A1 (en) * 2003-01-06 2004-07-29 Eli Lilly And Company Heteroaryl compounds
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
EP1594863A1 (en) * 2003-02-11 2005-11-16 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
PT1723128E (pt) 2004-01-06 2013-02-27 Novo Nordisk As Heteroaril-ureias e o seu uso como activadores da glicoquinase
WO2005080359A1 (en) 2004-02-18 2005-09-01 Astrazeneca Ab Benzamide derivatives and their use as glucokinae activating agents
JP4700684B2 (ja) * 2004-04-02 2011-06-15 ノバルティス アーゲー ２型糖尿病の処置に有用なグルコキナーゼアクティベーターとしてのスルホンアミド−チアゾロピリジン誘導体
CA2561157A1 (en) * 2004-04-02 2005-10-13 Novartis Ag Thiazolopyridine derivatives, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions
WO2005103021A1 (en) * 2004-04-21 2005-11-03 Prosidion Limited Tri(cyclo) substituted amide compounds
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
WO2005123132A2 (en) * 2004-06-17 2005-12-29 Novo Nordisk A/S Use of liver-selective glucokinase activators
BRPI0514147A (pt) * 2004-08-12 2008-05-27 Prosidion Ltd composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos de tratamento profilático ou terapêutico de uma condição onde a ativação de gk é desejável, de tratamento profilático ou terapêutico da hiperglicemia ou diabete e de prevenção da diabete em um ser humano que demosntra hiperglicemia pré-diabética ou toleráncia à glicose prejudicada, e, processo para a preparação do composto
WO2007006760A1 (en) 2005-07-08 2007-01-18 Novo Nordisk A/S Dicycloalkyl urea glucokinase activators
NZ575514A (en) 2005-07-09 2009-11-27 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
EP1910317B1 (en) 2005-07-20 2013-07-03 Eli Lilly And Company 1-amino linked compounds
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
JP2009509988A (ja) 2005-09-29 2009-03-12 サノフィ−アベンティス フェニル−及びピリジニル−１，２，４−オキサジアゾロン誘導体、その製造方法、及び医薬品としてのその使用
GT200600429A (es) * 2005-09-30 2007-04-30 Compuestos organicos
GT200600428A (es) * 2005-09-30 2007-05-21 Compuestos organicos
CA2626475A1 (en) * 2005-11-03 2007-05-10 Prosidion Limited Tricyclo substituted amides
PT1951658E (pt) 2005-11-17 2012-11-12 Lilly Co Eli Antagonistas do receptor do glucagon, preparação e utilizações terapêuticas
WO2007061923A2 (en) * 2005-11-18 2007-05-31 Takeda San Diego, Inc. Glucokinase activators
JP5302012B2 (ja) 2006-03-08 2013-10-02 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
WO2007143434A2 (en) 2006-05-31 2007-12-13 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents
BRPI0714526A2 (pt) 2006-08-24 2013-04-30 Univ Tennessee Res Foundation acilanilidas substituÍdas e seus mÉtodos de uso
CL2007003061A1 (es) 2006-10-26 2008-08-01 Astrazeneca Ab Compuestos derivados de 3,5-dioxi-benzamida; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada a traves de glk, tal como la diabetes tipo 2.
US7902248B2 (en) * 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
EP2091947A2 (en) 2006-12-20 2009-08-26 Takeda San Diego, Inc. Glucokinase activators
TW200831081A (en) 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
EP2125735B1 (en) 2007-02-28 2012-06-27 Advinus Therapeutics Private Limited 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application
WO2008111473A1 (ja) * 2007-03-07 2008-09-18 Kyorin Pharmaceutical Co., Ltd. グルコキナーゼ活性化物質
WO2008116107A2 (en) * 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators
ATE513830T1 (de) * 2007-09-21 2011-07-15 Sanofi Aventis Phenothiazin-derivate mit doppelbindung, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
PE20091313A1 (es) * 2008-01-15 2009-09-03 Lilly Co Eli (r)-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida cristalina
RU2010134411A (ru) 2008-01-18 2012-02-27 Астеллас Фарма Инк. (Jp) Фенилацетамидное производное
CA2722733C (en) 2008-04-28 2016-02-23 Kyorin Pharmaceutical Co., Ltd. Cyclopentylacrylamide derivative
NZ589084A (en) 2008-05-16 2012-06-29 Takeda San Diego Inc Glucokinase activators
EP2445908A1 (en) 2009-06-22 2012-05-02 Cadila Healthcare Limited Disubstituted benzamide derivatives as glucokinase (gk) activators
NZ598232A (en) 2009-07-31 2013-08-30 Cadila Healthcare Ltd Substituted benzamide derivatives as glucokinase (gk) activators
KR100970871B1 (ko) * 2009-11-30 2010-07-20 케이제이알디 (주) 바닥재 어셈블리 및 바닥재의 시공방법
MY159151A (en) 2009-12-04 2016-12-15 Nissan Chemical Ind Ltd 2-pyridone compounds
CN102959076B (zh) 2010-03-31 2015-09-16 斯克里普斯研究所 重编程细胞
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
KR102122941B1 (ko) 2012-07-13 2020-06-15 지티엑스, 인코포레이티드 선택적 안드로겐 수용체 조절자(sarms)를 이용한 안드로겐 수용체(ar) 양성 유방암의 치료 방법
WO2014077235A1 (ja) 2012-11-13 2014-05-22 大正製薬株式会社 ２－ピリドン化合物
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent
CA3093025A1 (en) 2018-06-12 2019-12-19 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8909574D0 (en) 1989-04-26 1989-06-14 Ici Plc Chemical process
US5169951A (en) 1990-04-23 1992-12-08 Ciba-Geigy Corporation Process for preparing nematicidal compositions
KR100455635B1 (ko) * 1999-03-29 2004-11-06 에프. 호프만-라 로슈 아게 글루코키나제 활성화제

Also Published As

Publication number Publication date
UY26483A1 (es) 2001-06-29
ATE305461T1 (de) 2005-10-15
US6353111B1 (en) 2002-03-05
ZA200203829B (en) 2003-08-14
CN1185219C (zh) 2005-01-19
YU41402A (sh) 2005-07-19
JP2003516980A (ja) 2003-05-20
IL150083A0 (en) 2002-12-01
HUP0203753A2 (hu) 2003-03-28
KR20020067555A (ko) 2002-08-22
EP1242397A1 (en) 2002-09-25
HRP20020514A2 (en) 2004-06-30
AR032752A1 (es) 2003-11-26
IL150083A (en) 2010-04-15
RU2245332C2 (ru) 2005-01-27
DE60022903D1 (de) 2006-02-09
PE20011022A1 (es) 2001-10-11
KR100502032B1 (ko) 2005-07-25
NO323142B1 (no) 2007-01-08
CN1411453A (zh) 2003-04-16
DE60022903T2 (de) 2006-07-06
AU781029B2 (en) 2005-04-28
GC0000264A (en) 2006-11-01
JP3824936B2 (ja) 2006-09-20
NO20022863L (no) 2002-06-14
CA2392903C (en) 2008-08-05
TWI262916B (en) 2006-10-01
MXPA02005874A (es) 2002-10-23
NZ518974A (en) 2004-04-30
WO2001044216A1 (en) 2001-06-21
EP1242397B1 (en) 2005-09-28
MA26855A1 (fr) 2004-12-20
DK1242397T3 (da) 2006-02-13
JO2180B1 (en) 2003-04-23
HK1054383A1 (en) 2003-11-28
HK1054383B (zh) 2005-04-22
ES2249322T3 (es) 2006-04-01
CZ20022412A3 (cs) 2002-10-16
HUP0203753A3 (en) 2004-12-28
MY125484A (en) 2006-08-30
CA2392903A1 (en) 2001-06-21
PL355815A1 (en) 2004-05-17
CO5050295A1 (es) 2001-06-27
AU2365201A (en) 2001-06-25

Similar Documents

Publication Publication Date Title
ATE278680T1 (de) Glukokinase aktivatoren
NO20022863L (no) Trans-olefiniske glycokinase aktivatorer
DE60044873D1 (de) Orientierte biopolymermembrane
DE122007000064I1 (de) Erythropoietinkonjugate
DE19983871T1 (de) Fönvorrichtung
DE60134470D1 (de) Para-amin substituierte phenylamid glukokinase activatoren
DK1311504T3 (da) Tetrazolyl-phenylacetamid-glucokinase-aktivatorer
DE10084676T1 (de) Einmallanzettvorrichtung
DE50002834D1 (de) Handstempel
ATE357433T1 (de) 4-pyrimidinyl-n-acyl-l-phenylanine
ATE297895T1 (de) 4-pyridinyl-n-acyl-l-phenylalanine
DE50000805D1 (de) Aufsitzspanner
DE10085008T1 (de) Oberflächenbehandlungsdüse
DE50003660D1 (de) Diacylhydrazinderivate
DE19983890T1 (de) Ventiltaktgebungsjustiereinrichtung
DE50001640D1 (de) Nahfeldoptische untersuchungsvorrichtung
NO20021850L (no) Hygromycinderivater
DE10082008D2 (de) Ausbeulgerät
ATE269311T1 (de) Benzoylpyridazine
ATE440824T1 (de) Nitro-sulfobenzamide
ATA107599A (de) Heizwasserbereiter
DE50002156D1 (de) Azofarbstoffmischungen
DE10085167T1 (de) Gangumschalteinrichtung
ATA732000A (de) Kachelofen
DE29900278U1 (de) Biobeton

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees